Wells Fargo raised the firm’s price target on Stryker (SYK) to $456 from $452 and keeps an Overweight rating on the shares. The firm notes the company’s 2025 investor meeting highlighted the potential for sustained 10% organic topline growth and double-digit EPS growth. Margin target of 150bps next 3 years was slightly better than expected. Key pipeline updates include Mako RPS hand-held robot, Wells adds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker’s Strategic Growth Plans and Market Leadership Reinforce Buy Rating
- Stryker’s Strategic Growth and Innovation Drive: Buy Rating Affirmed
- Stryker’s Robust Growth Trajectory and Strategic Initiatives Justify Buy Rating
- Stryker’s Strong Market Position and Growth Potential Justify Buy Rating with $410 Price Target
- Zimmer Biomet price target lowered to $112 from $122 at BTIG